Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-04-19
1998-06-23
Huff, Sheela
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 79, 435 791, 435 792, 435 793, 435 723, 436501, 436518, 436523, 436524, 436525, 436526, 436527, 436528, 436529, 436530, 436531, 436 64, 436813, G01N 3353, G01N 33574, G01N 33542, G01N 33543
Patent
active
057703779
ABSTRACT:
A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.
Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumours is also described and claimed.
REFERENCES:
patent: 5532348 (1996-07-01), Huibregtse et al.
patent: 5550023 (1996-08-01), Kinzler et al.
Lane, D.P., et al., "On the Regulation of the p53 Tumor Suppressor, and its Role in the Cellular Response to DNA Damage," Phil. R. Soc. Lond. B, 347:83-87 (1995).
Barak, Y., et al., "mdm2 expression is induced by wild type p53 activity," EMBO Journ., 12:461-468 (1993).
Barak, Y. & M. Oren, "Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest," EMBO Journ., 11:2115-2121 (1992).
Brown, D. R., et al., "The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein," Molec. Cell. Biol., 13:6849-6857 (1993).
Cahilly-Snyder, L., et al., "Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell," Somatic Cell and Molecular Genetics, 13:235-244 (1987).
Chen, J., et al., "Mapping of the p53 and mdm-2 interaction domains," Mol. Cell. Biol., 13:4107-4114 (1993).
Dyson, N., et al., "Adenovirus E1A Makes Two Distinct Contacts with the Retinoblastoma Protein," J. Virol., 66:4606-4611 (1992).
Dyson, N., et al., "Homologous Sequences in Adenovirus E1A and Human Papillomavirus E7 Proteins Mediate Interaction with the Same Set of Cellular Proteins," J. Virol., 66:6893-6902 (1992).
Farmer, G., et al., "Wild-type p53 activates transcription in vitro," Nature, 358:83-86 (1992).
Funk, W. D., et al., "A transcriptionally active DNA-binding site for human p53 protein complexes," Mol. Cell. Biol., 12:2866-2871 (1992).
Kern, S. E., et al., "Oncogenic forms of p53 inhibit p53-regulated gene expression," Science, 256:827-830 (1992).
Michalovitz, D., et al., "Conditional inhibition of transformation and of cell proliferation by a temperature-sensitve mutant of p53," Cell, 62:671-680 (1990).
Momand, J., et al., "The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation," Cell, 69:1237-1245 (1992).
Oliner, J.D., et al., "Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53," Nature, 362:857-860 (1993).
Unger, T., et al., "p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer", EMBO Journ., 11:1383-1390 (1992).
Picksley, S.M. & D.P. Lane, "The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?" BioEssays, 15:689-690 (1993).
Lin, J. et al., "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein," Genes & Develop., 8:1235-1246 (1994).
Schlichtholtz, B., et al., "The Immune Response to p53 in Breast Cancer Patients is Directed Against Immunodominant Epitopes Unrelated to Mutational Hot Spot," Canc. Res., 52:6380-6384 (1993).
Wu, X., et al., "The p53-mdm2 autoregulatory feedback loop," Genes & Develop., 7:1126-1132 (1993).
Picksley, S. M., et al., "Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides," Oncogene, 9:2523-2529 (1994).
Deffie, A., et al., "The tumor suppressor p53 regulates its own transcription," Mol. Cell. Biol., 13:3415-2423 (1993).
Liu, X., et al., "The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription," Mol. Cell. Biol., 13:3291-3300 (1993).
Oliner, J.D., et al, "Amplification of a gene encoding a p53-associated protein in hunan sarcomas," Nature, 358:80-83 (1992).
Lane, D., et al., Overheads presented in conjunction with talk given Oncogenes EMBL Symposium at Heidelberg on Apr. 20, 1994.
Picksley, S. M. and D. P. Lane, "p53 and Rb: their cellular roles", Current Opinion in Cell Biology 6:853-858 (1994).
Martin, K., et al., "Stimulation of E21F1/DP1 Transcriptional Activity by MDM2 Oncoprotein," Nature 375:691-698 (1995).
Marston, N.J., et al., "Interaction of p53 with MDM2 is Independent of E6 and Does Not Mediate Wild Type Transformation Suppressor Function," Oncogene 9:2707-2716 (1994).
Lane David Philip
Picksley Steven Michael
Dreger Walter H.
Huff Sheela
Kresnak Mark T.
University of Dundee
LandOfFree
Interruption of binding of MDM2 and P53 protein and therapeutic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interruption of binding of MDM2 and P53 protein and therapeutic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interruption of binding of MDM2 and P53 protein and therapeutic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1393413